GlassScriptPhysician profile
James R Hale
NPI 1215903125
$22,249.21
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,779 · 2020: $3,140 · 2021: $488 · 2022: $337 · 2023: $369 · 2024: $992 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,700 · Honoraria: $5,000 · Food and Beverage: $1,689 · Entertainment: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,700.00 |
| Honoraria | $5,000.00 |
| Food and Beverage | $1,689.42 |
| Entertainment | $116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nordic Pharma, INC. | $7,700.00 | 2025 | Lacrifill |
| Oculus, INC. | $6,750.00 | 2019-2021 | |
| Optos, INC. | $5,159.23 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $849.82 | 2019-2025 | Total30, Precision 1, Precision7 |
| Lumenis Be INC | $574.79 | 2024 | Optilight |
| Coopervision INC. | $375.74 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Lkc Technologies, INC. | $265.91 | 2023-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.26 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $131.17 | 2022-2025 | Infuse, Miebo, Xiidra |
| Carl Zeiss Meditec, INC. | $62.50 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $42.64 | 2019-2022 | |
| Carl Zeiss Meditec Ag | $36.60 | 2020 | |
| Sun Pharmaceutical Industries INC. | $32.42 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $24.71 | 2022 | |
| Allergan, INC. | $21.29 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $20.94 | 2021 | |
| Oyster Point Pharma, INC. | $20.48 | 2024 | Tyrvaya |
| Lombart Brothers, INC. | $14.61 | 2020 | |
| Biotissue Holdings INC. | $14.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.